Patents Assigned to Shiratori Pharmaceutical Co., Ltd.
-
Publication number: 20230310347Abstract: Provided is a bactericide having an excellent bactericidal effect against Propionibacterium acnes. This bactericide contains the following components (A) and (B) as active ingredients: (A) phenol derivative; and (B) One or more ingredients selected from limonene, ?-terpinene, ?-terpinene, terpinen-4-ol, and tea tree oil.Type: ApplicationFiled: September 1, 2021Publication date: October 5, 2023Applicant: SHIRATORI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi YOSHINO, Sho KAWATOBI
-
Patent number: 11173158Abstract: Disclosed is a means for improving the symptoms of a cerebral dysfunction. The present inventors made a new discovery that the activity of brain aromatic monoamines increases when sepiapterin is administered peripherally. Disclosed, therefore, is a medicinal agent, which contains at least sepiapterin or a salt thereof, for preventing or improving cerebral dysfunction. Also disclosed is a beverage/food, which contains at least sepiapterin or a salt thereof, for preventing or improving cerebral dysfunction. Unlike tetrahydrobiopterin and the like, sepiapterin can control reductions in the brain neuron levels of brain aromatic monoamines (serotonin, dopamine, noradrenaline, and the like) and increase the activity thereof even when administered peripherally.Type: GrantFiled: June 18, 2019Date of Patent: November 16, 2021Assignees: PTC Therapeutics MP, Inc., Shiratori Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Hasegawa, Shin Aizawa
-
Patent number: 9181254Abstract: To provide a method for producing sepiapterin, lactoylpterin or tetrahydrolactoylpterin. Sepiapterin, lactoylpterin and tetrahydrolactoylpterin are produced at high yield through the following reaction scheme.Type: GrantFiled: May 7, 2013Date of Patent: November 10, 2015Assignee: SHIRATORI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Shizuaki Murata, Yasuhiro Kuroda
-
Publication number: 20150119574Abstract: To provide a method for producing sepiapterin, lactoylpterin or tetrahydrolactoylpterin. Sepiapterin, lactoylpterin and tetrahydrolactoylpterin are produced at high yield through the following reaction scheme.Type: ApplicationFiled: May 7, 2013Publication date: April 30, 2015Applicant: SHIRATORI PHARMACEUTICAL CO., LTD.Inventors: Hiroshi Yoshino, Taichi Komoda, Yuichi Shiro, Shunichi Murata, Shizuaki Murata, Yasuhiro Kuroda
-
Patent number: 8039617Abstract: A method for selectively producing stable alpha form crystals of sapropterin hydrochloride is provided. In this method, the alpha form crystal of sapropterin hydrochloride is produced by dissolving sapropterin hydrochloride with hydrochloric acid at a concentration of not less than 4 mol/L at not less than 70 degrees C.; adding heated ethanol to the solution; and cooling the solution at a cooling rate of not faster than 3 degrees C./min to a temperature of 40 to 55 degrees C. to precipitate the crystals.Type: GrantFiled: April 13, 2006Date of Patent: October 18, 2011Assignees: Shiratori Pharmaceutical Co., Ltd., Daiichi Sankyo Company, LimitedInventors: Katsumi Hotoda, Hiroomi Kiyono, Shinnosuke Tazawa
-
Publication number: 20090270619Abstract: A method for selectively producing stable alpha form crystals of sapropterin hydrochloride is provided. In this method, the alpha form crystal of sapropterin hydrochloride is produced by dissolving sapropterin hydrochloride with hydrochloric acid at a concentration of not less than 4 mol/L at not less than 70 degrees C.; adding heated ethanol to the solution; and cooling the solution at a cooling rate of not faster than 3 degrees C./min to a temperature of 40 to 55 degrees C. to precipitate the crystals.Type: ApplicationFiled: April 13, 2006Publication date: October 29, 2009Applicant: Shiratori Pharmaceutical Co., Ltd.Inventors: Katsumi Hotoda, Hiroomi Kiyono, Shinnosuke Tazawa
-
Patent number: 7582799Abstract: The present invention provides an industrially advantageous process for producing hydrazone derivative represented by the formula (5), which is shown by the following reaction formula.Type: GrantFiled: April 27, 2006Date of Patent: September 1, 2009Assignees: Shiratori Pharmaceutical Co., Ltd., Asubio Pharma Co., Ltd.Inventors: Hiroshi Yoshino, Kentaro Kobayashi, Yuichi Shiro
-
Publication number: 20090076305Abstract: The present invention provides an industrially advantageous process for producing hydrazone derivative represented by the formula (5), which is shown by the following reaction formula.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicants: Shiratori Pharmaceutical Co., Ltd., Asubio Pharma Co., Ltd.Inventors: Hiroshi Yoshino, Kentaro Kobayashi, Yuichi Shiro
-
Patent number: 7361759Abstract: To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants. A method for porducing a biopterin derivative represented by the formula (6): wherein R1 and R2, which are the same or different from each other, each represents a hydrogen atom, an alkyl group, or an aryl group, comprising: reacting a compound belonging to triacetoxy-5-deoxy-L-arabinose phenylhydrazones represented by the formula (4): wherein R1 and R2 are the same as defined above, with 6-hydroxy-2,4,5-triaminopyrimidine (5) under catalytic influence of a Lewis acid in an aqueous solvent.Type: GrantFiled: February 28, 2005Date of Patent: April 22, 2008Assignees: Shiratori Pharmaceutical Co., Ltd, Asubio Pharma Co., Ltd.Inventor: Shinnosuke Tazawa
-
Publication number: 20060142573Abstract: To provide a method for producing L-biopterin on a large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants.Type: ApplicationFiled: February 28, 2005Publication date: June 29, 2006Applicants: Shiratori Pharmaceutical Co., Ltd., DAIICHI SUNTORY PHARMA CO., LTD.Inventor: Shinnosuke Tazawa
-
Patent number: 6352685Abstract: The object of the invention is to provide a new external preparation for skin having high melanine formation inhibition and also anti-aging effect, and desired drug effect can be obtained without degradation in a pharmaceutical preparation. The external preparation for skin includes the extract of Pueraria mirifica in conbination with an active ingredient selected from the group consisting of a whitening agent, an anti-oxidant, an anti-inflammation agent, an ultraviolet-ray shielding ingredient, a cell activation agent and humectant.Type: GrantFiled: December 22, 2000Date of Patent: March 5, 2002Assignees: Kosé Corporation, Shiratori Pharmaceutical Co., Ltd.Inventors: Taku Hoshino, Osamu Sakata, Masahiro Moriyama, Yoshihiro Higuchi
-
Patent number: 4713454Abstract: (6R)-Tetrahydro-L-biopterin of the following formula: ##STR1## is prepared by catalytically reducing L-erythrobiopterin or an acyl derivative thereof in the presence of an amine, at pH 10-13 and with a platinum-base catalyst and when one or more acyl groups still remain, then removing the acyl groups. (6R)-Tetrahydro-L-biopterin is effective for the treatment of certain serious neuroses and malignant hyperphenylalaniemia. The present invention has succeeded in preparing (6R)-tetrahydro-L-biopterin at a high asymmetric ration R/S and moreover with a high yield. Since the process of this invention makes use of an amine as a base, the process is free from admixture of any inorganic salt and can hence provide high-purity crystals with ease.Type: GrantFiled: January 23, 1986Date of Patent: December 15, 1987Assignees: Shiratori Pharmaceutical Co., Ltd., Suntory LimitedInventors: Hideaki Sakai, Tadashi Kanai